Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $1.91 USD
Change Today +0.01 / 0.53%
Volume 49.3K
STXS On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
As of 8:10 PM 05/1/15 All times are local (Market data is delayed by at least 15 minutes).

stereotaxis inc (STXS) Snapshot

Open
$1.88
Previous Close
$1.90
Day High
$2.02
Day Low
$1.88
52 Week High
05/6/14 - $4.07
52 Week Low
12/16/14 - $1.32
Market Cap
40.0M
Average Volume 10 Days
102.2K
EPS TTM
$-0.27
Shares Outstanding
20.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for STEREOTAXIS INC (STXS)

Related News

No related news articles were found.

stereotaxis inc (STXS) Related Businessweek News

No Related Businessweek News Found

stereotaxis inc (STXS) Details

Stereotaxis, Inc. designs, manufactures, and markets robotic systems and instruments for the treatment of abnormal heart rhythms in the United States and internationally. Its products include Niobe ES robotic system that enables physicians to complete interventional procedures by providing image guided delivery of catheters and guide wires through the blood vessels and chambers of the heart to treatment sites; and Vdrive system, which offers navigation and stability for the diagnostic and ablation devices designed to enhance interventional procedures. The company also offers Odyssey solution, which provides integrated real-time information solution to manage, control, record, and share procedures across networks worldwide. In addition, it provides disposables and other accessories, such as QuikCAS automated catheter advancement disposables for the remote advancement of electrophysiology catheters; CARTO RMT navigation and ablation system, CELSIUS RMT, NAVISTAR RMT, NAVISTAR RMT DS, NAVISTAR RMT THERMOCOOL, and CELSIUS RMT THERMOCOOL irrigated tip diagnostic/ablation steerable tip catheters; and Pegasus coronary guidewire for cardiology procedures. Further, the company offers V-CAS catheter and V-CAS Deflect integrated catheter advancement systems; and V-loop circular and V-Sono ICE catheter manipulators. Stereotaxis, Inc. has strategic alliances with Siemens AG Medical Solutions; Philips Medical Systems; and Biosense Webster, Inc. The company markets its products through direct sales force, distributors, and sales agents. Stereotaxis, Inc. was founded in 1990 and is headquartered in St. Louis, Missouri.

133 Employees
Last Reported Date: 03/16/15
Founded in 1990

stereotaxis inc (STXS) Top Compensated Officers

Chairman of the Board, Chief Executive Office...
Total Annual Compensation: $662.3K
Chief Financial Officer and Principal Account...
Total Annual Compensation: $337.5K
Senior Vice President, General Counsel and Se...
Total Annual Compensation: $423.8K
Vice President of Human Resources
Total Annual Compensation: $315.0K
Senior Vice President of Marketing & Business...
Total Annual Compensation: $435.0K
Compensation as of Fiscal Year 2014.

stereotaxis inc (STXS) Key Developments

Stereotaxis Inc. Extends Silicon Valley Bank Credit Facility by Three Years

Stereotaxis Inc. announced that it has extended the maturity of its revolving credit facility with Silicon Valley Bank (SVB) by three years to March 31, 2018. The amended agreement maintains the existing line capacity of $10 million, which was increased from $3 million in 2014.

Stereotaxis Inc. Auditor Raises 'Going Concern' Doubt

Stereotaxis Inc. filed its 10-K on Mar 16, 2015 for the period ending Dec 31, 2014. In this report its auditor, Ernst & Young LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.

Stereotaxis Inc. Reports Unaudited Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014

Stereotaxis Inc. reported unaudited earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company reported total revenue of $9,754,968 compared to $9,068,026 a year ago. Operating income was $313,533 compared to operating loss of $2,424,138 a year ago. Net income was $856,215 or $0.04 per basic and diluted share compared to net loss of $3,962,208 or $0.23 per basic and diluted share a year ago. For the year, the company reported total revenue of $35,011,276 compared to $38,031,081 a year ago. Operating loss was $5,384,664 compared to $8,840,474 a year ago. Net loss was $5,202,441 or $0.26 per basic and diluted share compared to $68,757,589 or $5.95 per basic and diluted share a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
STXS:US $1.91 USD +0.01

STXS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bacterin International Holdings Inc $4.25 USD +0.05
Biolase Inc $2.14 USD +0.11
Bovie Medical Corp $3.01 USD -0.088
Cogentix Medical Inc $1.61 USD +0.026
Hansen Medical Inc $0.85 USD -0.0301
View Industry Companies
 

Industry Analysis

STXS

Industry Average

Valuation STXS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.1x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 0.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact STEREOTAXIS INC, please visit www.stereotaxis.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.